Jefferies Financial Group Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Jefferies Financial Group Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $10.82B | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $10.52B | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $7.44B | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | $7.15B | Jan 28, 2025 |
| FY2023 | Nov 30, 2021 | $8.95B | Jan 26, 2024 |
| FY2022 | Nov 30, 2020 | $6.88B | Jan 27, 2023 |
| FY2021 | Nov 30, 2019 | $5.36B | Jan 28, 2022 |
| FY2020 | Nov 30, 2018 | $5.01B | Jan 29, 2021 |
| FY2019 | Dec 31, 2017 | $5.05B | Jan 29, 2020 |
| FY2017 | Dec 31, 2016 | $10.88B | Feb 27, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $5.55B | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $4.86B | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $3.23B | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | $4.74B | Jan 28, 2025 |
| FY2023 | Nov 30, 2021 | $6.14B | Jan 26, 2024 |
| FY2022 | Nov 30, 2020 | $3.92B | Jan 27, 2023 |
| FY2021 | Nov 30, 2019 | $2.79B | Jan 28, 2022 |
| FY2020 | Nov 30, 2018 | $3.12B | Jan 29, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Nov 30, 2021 | $1.67B | Jan 28, 2022 |
| FY2020 | Nov 30, 2020 | $307.27M | Jan 29, 2021 |
| FY2020 | Aug 31, 2020 | $304.41M | Jan 29, 2021 |
| FY2020 | May 31, 2020 | $44.92M | Jan 29, 2021 |
| FY2020 | Feb 29, 2020 | $113.01M | Jan 29, 2021 |
| FY2020 | Nov 30, 2019 | $195.54M | Jan 29, 2021 |
| FY2020 | Aug 31, 2019 | $48.48M | Jan 29, 2021 |
| FY2020 | May 31, 2019 | $670.76M | Jan 29, 2021 |
| FY2020 | Feb 28, 2019 | $44.81M | Jan 29, 2021 |
| FY2019 | Nov 30, 2018 | ($20.37M) | Jan 29, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2009 | Dec 31, 2009 | ($250.97M) | Feb 26, 2010 |
| FY2009 | Dec 31, 2008 | ($367.96M) | Feb 26, 2010 |
| FY2009 | Dec 31, 2007 | ($61.24M) | Feb 26, 2010 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $17.58M | Feb 25, 2013 |
| FY2011 | Dec 31, 2011 | $22.15M | Feb 27, 2012 |
| FY2010 | Dec 31, 2010 | $5.50M | Feb 25, 2011 |
| FY2010 | Dec 31, 2009 | $3.50M | Feb 25, 2011 |
| FY2010 | Dec 31, 2008 | $14.00M | Feb 25, 2011 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Nov 30, 2023 | ($1.93B) | Jan 26, 2024 |
| FY2023 | Nov 30, 2022 | $1.80B | Jan 26, 2024 |
| FY2023 | Nov 30, 2021 | $1.58B | Jan 26, 2024 |
| FY2022 | Nov 30, 2020 | $2.06B | Jan 27, 2023 |
| FY2021 | Nov 30, 2019 | ($827.84M) | Jan 28, 2022 |
| FY2020 | Nov 30, 2018 | $691.10M | Jan 29, 2021 |
| FY2019 | Dec 31, 2017 | $788.29M | Jan 29, 2020 |
| FY2017 | Dec 31, 2016 | $608.85M | Feb 27, 2018 |
| FY2017 | Dec 31, 2015 | ($761.76M) | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | ($987.16M) | Feb 27, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $207.47M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $250.58M | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $1.16M | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | $224.30M | Jan 28, 2025 |
| FY2023 | Nov 30, 2021 | $165.61M | Jan 26, 2024 |
| FY2022 | Nov 30, 2020 | $176.96M | Jan 27, 2023 |
| FY2013 | Dec 31, 2013 | $137.13M | Feb 28, 2014 |
| FY2013 | Dec 31, 2012 | $71.33M | Feb 28, 2014 |
| FY2013 | Dec 31, 2011 | $38.59M | Feb 28, 2014 |
| FY2012 | Dec 31, 2010 | $44.34M | Feb 25, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $76.01B | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $64.36B | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | $57.91B | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | $51.06B | Jan 26, 2024 |
| FY2022 | Nov 30, 2021 | $56.11B | Jan 27, 2023 |
| FY2021 | Nov 30, 2020 | $53.12B | Jan 28, 2022 |
| FY2021 | Nov 30, 2019 | $49.46B | Jan 28, 2022 |
| FY2020 | Nov 30, 2018 | $47.13B | Jan 29, 2021 |
| FY2019 | Dec 31, 2017 | $47.17B | Jan 29, 2020 |
| FY2017 | Dec 31, 2016 | $45.07B | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $65.37B | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $54.13B | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | $48.10B | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | $40.63B | Jan 26, 2024 |
| FY2022 | Nov 30, 2021 | $45.38B | Jan 27, 2023 |
| FY2021 | Nov 30, 2020 | $43.53B | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | $39.71B | Jan 29, 2021 |
| FY2019 | Nov 30, 2018 | $36.91B | Jan 29, 2020 |
| FY2017 | Dec 31, 2017 | $36.48B | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $34.31B | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $10.57B | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $10.16B | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | $9.71B | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | $10.23B | Jan 26, 2024 |
| FY2022 | Nov 30, 2021 | $10.55B | Jan 27, 2023 |
| FY2021 | Nov 30, 2020 | $9.40B | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | $9.58B | Jan 29, 2021 |
| FY2019 | Nov 30, 2018 | $10.06B | Jan 29, 2020 |
| FY2017 | Dec 31, 2017 | $10.11B | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $10.13B | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $1.84B | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $1.83B | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $1.85B | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | $1.74B | Jan 28, 2025 |
| FY2023 | Nov 30, 2021 | $1.75B | Jan 26, 2024 |
| FY2022 | Nov 30, 2020 | $1.75B | Jan 27, 2023 |
| FY2020 | Nov 30, 2019 | $1.74B | Jan 29, 2021 |
| FY2019 | Nov 30, 2018 | $1.70B | Jan 29, 2020 |
| FY2017 | Dec 31, 2017 | $1.72B | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $1.72B | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $8.57B | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $8.27B | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | $7.85B | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | $8.42B | Jan 26, 2024 |
| FY2022 | Nov 30, 2021 | $7.94B | Jan 27, 2023 |
| FY2021 | Nov 30, 2020 | $6.53B | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | $5.93B | Jan 29, 2021 |
| FY2019 | Nov 30, 2018 | $5.61B | Jan 29, 2020 |
| FY2017 | Dec 31, 2017 | $4.70B | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $4.65B | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $14.04B | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $12.15B | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | $8.53B | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | $9.70B | Jan 26, 2024 |
| FY2022 | Nov 30, 2021 | $10.76B | Jan 27, 2023 |
| FY2021 | Nov 30, 2020 | $9.06B | Jan 28, 2022 |
| FY2021 | Nov 30, 2019 | $7.68B | Jan 28, 2022 |
| FY2020 | Nov 30, 2018 | $5.26B | Jan 29, 2021 |
| FY2019 | Dec 31, 2017 | $5.28B | Jan 29, 2020 |
| FY2017 | Dec 31, 2016 | $3.81B | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $15.90B | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $13.53B | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | $9.70B | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | $8.77B | Jan 26, 2024 |
| FY2022 | Nov 30, 2021 | $9.13B | Jan 27, 2023 |
| FY2021 | Nov 30, 2020 | $8.35B | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | $8.34B | Jan 29, 2021 |
| FY2019 | Nov 30, 2018 | $7.62B | Jan 29, 2020 |
| FY2017 | Dec 31, 2017 | $7.89B | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $7.38B | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | 2 | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | 3 | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | 1 | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | 3 | Jan 28, 2025 |
| FY2023 | Nov 30, 2021 | 6 | Jan 26, 2024 |
| FY2020 | Nov 30, 2020 | 1 | Jan 29, 2021 |
| FY2020 | Aug 31, 2020 | 1 | Jan 29, 2021 |
| FY2020 | May 31, 2020 | 0 | Jan 29, 2021 |
| FY2020 | Feb 29, 2020 | 0 | Jan 29, 2021 |
| FY2020 | Nov 30, 2019 | 0 | Jan 29, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | 2 | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | 2 | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | 1 | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | 3 | Jan 28, 2025 |
| FY2023 | Nov 30, 2021 | 6 | Jan 26, 2024 |
| FY2020 | Nov 30, 2020 | 1 | Jan 29, 2021 |
| FY2020 | Aug 31, 2020 | 1 | Jan 29, 2021 |
| FY2020 | May 31, 2020 | 0 | Jan 29, 2021 |
| FY2020 | Feb 29, 2020 | 0 | Jan 29, 2021 |
| FY2020 | Nov 30, 2019 | 0 | Jan 29, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Nov 30, 2023 | 210.63M | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | 226.13M | Jan 26, 2024 |
| FY2022 | Nov 30, 2021 | 243.54M | Jan 27, 2023 |
| FY2021 | Nov 30, 2020 | 249.75M | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | 291.64M | Jan 29, 2021 |
| FY2019 | Nov 30, 2018 | 307.52M | Jan 29, 2020 |
| FY2017 | Dec 31, 2017 | 356.23M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | 359.43M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | 362.62M | Feb 27, 2017 |
| FY2015 | Dec 31, 2014 | 367.50M | Feb 19, 2016 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $374.13M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $302.96M | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $278.60M | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | $280.10M | Jan 28, 2025 |
| FY2023 | Nov 30, 2021 | $222.80M | Jan 26, 2024 |
| FY2022 | Nov 30, 2020 | $160.94M | Jan 27, 2023 |
| FY2021 | Nov 30, 2019 | $149.65M | Jan 28, 2022 |
| FY2020 | Nov 30, 2018 | $151.76M | Jan 29, 2021 |
| FY2019 | Dec 31, 2017 | $117.41M | Jan 29, 2020 |
| FY2017 | Dec 31, 2016 | $91.30M | Feb 27, 2018 |